Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Corporate Presentation Corporate Fact Sheet

Latest News

IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023

IMUNON to Hold First Quarter 2023 Financial Results and Business Update Conference Call on Thursday, May 11, 2023

May 4, 2023

IMUNON Presents Poster at the American Association for Cancer Research Annual Meeting Demonstrating Preclinical Immune Response of IMNN-001

April 19, 2023

Financial Events

Imunon’s First Quarter 2023 Financial Results

May 11, 2023 at 11:00 AM EDT

Fourth Quarter 2022 Financial Results

March 30, 2023 at 11:00 AM EDT